Elan Corp., Ethical deal

The companies will develop several oral controlled-release and transdermal products. ELN will receive access to ETHCY's Multipor oral controlled-release technology and transdermal controlled-release technologies. Technologies that emerge from the collaboration will be the property of both companies.

ELN (Athlone, Ireland) paid an $8 million license fee for access to the technology and for the right to manufacture certain of ETHCY's products. ETHCY also will receive development payments, a share of license fees, and royalties of 5-8 percent. ...